Abstract: Disclosed herein are polymorphic and amorphous forms of anhydrate, hydrate, and solvates of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide and methods of using such compositions for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging. Further disclosed are methods of making such polymorphic and amorphous forms.

Abstract: The present invention provides compounds of formula (I) wherein A, R1, R2 and R3 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments.

Abstract: The present description relates to methods of treating spinocerebellar ataxia type 3 (SCA3) using substituted thieno[3,2-b]pyridine compounds, forms, and pharmaceutical compositions thereof.

Abstract: The present description relates to methods of treating spinocerebellar ataxia type 3 (SCA3) using substituted thieno[3,2-d]pyrimidine compounds, forms, and pharmaceutical compositions thereof.

Abstract: The present description relates to methods of treating spinocerebellar ataxia type 3 (SCA3) using substituted pyrrolo[2,3-d]pyrimidine compounds, forms, and pharmaceutical compositions thereof.

Abstract: Compounds that selectively inhibit pathological production of human vascular endothelial growth factor (VEGF) and compositions comprising such Compounds are described. Compounds that inhibit viral replication or the production of viral RNA or DNA or viral protein and compositions comprising such Compounds are described. Also described are methods of reducing VEGF using such Compounds and methods for treating cancer and non-neoplastic conditions involving the administration of such Compounds. Further described are methods of inhibiting viral replication or the production of viral RNA or DNA or viral protein using such Compounds and methods for treating viral infections, involving the administration of such Compounds. The Compounds may be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatments.

Abstract: Disclosed is a parametric feature-based 3D CAD system that allows multiple users to simultaneously edit a parametric feature-based 3D CAD model consisting of 3D parts and assemblies of those parts (3D Model). Several CAD users, each using their own computer, phone, or tablet, can edit the same 3D Model at the same time. Editing may be separate and simultaneous—there is no need for users to worry about locking, checking out, or otherwise restricting each other's access to 3D Models. Within each user's editing interface, the model may be presented in different representations, with edits to any representation applied and displayed across all representations.

Abstract: The present disclosure provides compounds useful as anesthetics, such as topical anesthetics, of general formula (VIIIk): wherein: R2?H or Me; R3?H or Me; R4=Alkyl; R5?O-Alkyl; and Alkyl=aliphatic C1-C4 alkyl. The present disclosure further provides methods of making compounds of general formula (VIIIk), compositions comprising a therapeutically effective amount of a compound of general formula (VIIIk), and methods of treating or preventing pain in a subject by administering (e.g., topically applying) compositions comprising an effective amount of a compound of general formula (VIIIk) to the subject.

Abstract: The present disclosure provides compounds useful as anesthetics, such as topical anesthetics, of general formula (XIII): wherein: R8=NH2, NH(Me), N(Me)2, The present disclosure further provides methods of making compounds of general formula (XIII), compositions comprising a therapeutically effective amount of a compound of general formula (XIII), and methods of treating or preventing pain in a subject by administering (e.g., topically applying) compositions comprising an effective amount of a compound of general formula (XIII) to the subject.

Abstract: The present disclosure provides compounds useful as anesthetics, such as topical anesthetics, of general formula (VIIIi): wherein: R2?H or Me; R3?H or Me; R4=Alkyl; R5?O-Alkyl; and Alkyl=aliphatic C1-C4 alkyl. The present disclosure further provides methods of making compounds of general formula (VIIIi), compositions comprising a therapeutically effective amount of a compound of general formula (VIIIi), and methods of treating or preventing pain in a subject by administering (e.g., topically applying) compositions comprising an effective amount of a compound of general formula (VIIIi) to the subject.

Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heterocyclic and heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.

Abstract: The present disclosure provides compounds useful as anesthetics, such as topical anesthetics, of general formula (VIIIg): wherein: R2=H or Me; R3=H or Me; R4=Alkyl; R5=O-Alkyl; and Alkyl=aliphatic C1-C4 alkyl. The present disclosure further provides methods of making compounds of general formula (VIIIg), compositions comprising a therapeutically effective amount of a compound of general formula (VIIIg), and methods of treating or preventing pain in a subject by administering (e.g., topically applying) compositions comprising an effective amount of a compound of general formula (VIIIg) to the subject.

Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 4-(p-quinolyl)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating other disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, Parkinson's disease, and pervasive developmental disorders such as autism are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

Abstract: The present invention provides compounds of formula (I) wherein A, R1, R2 and R3 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments.

Abstract: The present disclosure provides compounds useful as anesthetics, such as topical anesthetics, of general formula (VIIIk): wherein: R2=H or Me; R3=H or Me; R4=Alkyl; R5=O-Alkyl; and Alkyl=aliphatic C1-C4 alkyl. The present disclosure further provides methods of making compounds of general formula (VIIIm), compositions comprising a therapeutically effective amount of a compound of general formula (VIIIm), and methods of treating or preventing pain in a subject by administering (e.g., topically applying) compositions comprising an effective amount of a compound of general formula (VIIIm) to the subject.

Abstract: The present disclosure provides compounds useful as anesthetics, such as topical anesthetics, of general formula (VI): wherein: R1 is H, Cl, F, —CF3, —OCF3, —OMe, or methyl; R8 is selected from the group consisting of: —NH2, —N(H)Alk, —N(Alk)2, R7 is H or alkyl; m is 3 to 6; p is 1 to 4; q is 1 to 4; p+g is 3 to 6; and each Alk is independently an aliphatic carbon group consisting of 1 to 6 carbon atoms, and methods of making and using same.

Abstract: An example augmented reality system includes: obtaining information about an instance of a device; recognizing the instance of the device based on the information; selecting a digital twin for the instance of the device, with the digital twin being unique to the instance of the device; and generating augmented reality content based on the digital twin and an actual graphic of the instance of the device.

Abstract: The present disclosure provides compounds useful as anesthetics, such as topical anesthetics, of general formula (I): wherein: R1 is H, —OMe, Me, or one or more electron withdrawing groups; R2 and R3 are each independently H or alkyl or, taken together, form a 4- to 8-membered heterocyclic ring with the adjacent nitrogen atom; R4 is H or alkyl; R5 is H or one or more electron donating groups; and n is 1 to 4. The present disclosure further provides compositions comprising a therapeutically effective amount of a compound of general formula (I), and methods of treating or preventing pain in a subject by administering (e.g., topically applying) such compositions to the subject.

Abstract: Disclosed herein is pharmaceutical compositions of Compound 1, and/or the hydroquinone form thereof, and methods useful for treating or suppressing a disease or disorder such as an ?-synucleinpathy, a tauopathy, an autistic spectrum disorder, a pervasive developmental disorder, a liver disease, and liver damage in a subject using such pharmaceutical compositions.

Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted monocyclic heteroaryl compounds of Formula (I) or Formula (II), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.